Pascal Biosciences Engages CFN Media to Build New Investor Audience

SEATTLE, June 19, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced that Pascal Biosciences (TSX-V:PAS) has engaged CFN Media to conduct a 3-month investor and market visibility program to begin on June 19, 2018.

“Pascal Biosciences, a Vancouver, BC and Seattle, WA-based biotechnology company, has discovered that certain cannabinoids stimulate the immune system to destroy tumor cells,” said Frank Lane, President of CFN Media. “We’re excited to be working with the company as it looks to bring its R&D-driven products to market to benefit patients.”

“At Pascal, we are excited by the potential of cannabinoids for improving cancer treatment. We are looking forward to working with CFN Media to develop our investor visibility,” said Pascal Biosciences CEO and President, Dr. Patrick Gray.

CFN Media will leverage its powerful content platform and extensive reach into mainstream and cannabis-focused investor audiences and media across North America to attract high-quality investors to Pascal Bioscience Inc. while elevating the company’s financial brand.

Learn how to become a CFN Media client company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

About CFN Media

CFN Media (CannabisFN), the leading agency and financial media network dedicated to the worldwide cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Private and public marijuana companies in the US and Canada rely on CFN Media to succeed in the capital markets.

About Pascal Bioscience Inc.

Pascal’s three significant technologies are:

  1. Utilizing proprietary screening systems for identifying novel compounds that are able to restore immune recognition and killing of cancer cells;
  2. Exploiting the regulation of specific calcium channels expressed by cells of the immune system. By regulating these calcium channels, immune activity can be controlled to combat cancers, infections and autoimmune diseases; and
  3. Developing a therapeutic monoclonal antibody for B-cell precursor acute lymphoblastic leukemia, the most common childhood leukemia, in collaboration with the University of New Mexico.


The above article is sponsored content. Emerging Growth LLC, which owns and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation:


Frank Lane
206 369 7050

Primary Logo

Back to news